Cancer screening

Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform

Retrieved on: 
Thursday, April 8, 2021
Medicine, Cancer, Health, Medical terminology, Infectious causes of cancer, Cancer screening, Breast cancer, Screening, Colorectal cancer, Epidemiology of cancer, Artificial intelligence in healthcare

The patent application specifically covers methods for capturing consistent data from infrared spectroscopy readers, as well as the application of various artificial intelligence algorithm development methods to the data.

Key Points: 
  • The patent application specifically covers methods for capturing consistent data from infrared spectroscopy readers, as well as the application of various artificial intelligence algorithm development methods to the data.
  • TBIA represents a potentially game-changing approach to cancer detection because we will be able to run different artificial intelligence-developed algorithms for multiple cancer types on the same blood sample.
  • While the focus is initially on improving the diagnosis of breast cancer and colon cancer using this method, the potential applies to all cancers.
  • We are positioning for TBIA to become a routine screening test done for cancer in a variety of patient screening settings worldwide.

Oncologists Remind America: Time To Get Cancer Screenings Back On Track

Retrieved on: 
Thursday, April 8, 2021
Medicine, Cancer, Clinical medicine, Cancer screening, Medical terminology, Prevention, Screening, Breast cancer, Colorectal cancer

"COVID-19 has caused many people to delay recommended cancer screenings, which are now at dangerously low levels.

Key Points: 
  • "COVID-19 has caused many people to delay recommended cancer screenings, which are now at dangerously low levels.
  • "It's safer to get screened now, rather than delaying getting checked for cancer, because early detection catches cancer when it's most treatable.
  • A study published in the November issue of the peer-reviewed journal JCO Clinical Cancer Informatics showed a considerable drop in cancer screening, diagnosis, and treatment for older adults in 2020, including an 85 percent decline in breast cancer screenings and a 75 percent decline for colon cancer screenings.
  • "Through this campaign we will not only be raising awareness of the importance of getting cancer screenings back on track, but also providing important support services to help overcome any barriers that individuals need to access their cancer screenings."

NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Thursday, April 8, 2021
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Cancer screening, NanoString Technologies, Branches of biology, Clinical medicine, Medicine, American Association for Cancer Research, Molecular biology, Breast cancer, Transcriptomics technologies

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of spatial biology abstracts that will be presented at the 2021 meeting of the American Association of Cancer Research (AACR), which will be held virtually from April 10 - 15, 2021.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of spatial biology abstracts that will be presented at the 2021 meeting of the American Association of Cancer Research (AACR), which will be held virtually from April 10 - 15, 2021.
  • Four of the eight abstracts will be presented by investigators from the GeoMx Breast Cancer Consortium (GBCC), an international network of breast cancer researchers.
  • Transcriptome profiling was performed for a cohort of breast cancer lumpectomies using the Cancer Transcriptomic Atlas (CTA) assay on the GeoMx DSP platform.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Exact Sciences schedules first quarter 2021 earnings call

Retrieved on: 
Thursday, April 8, 2021
Medical genetics, Branches of biology, Exact Sciences, Cancer screening, Cancer, Oncotype, Life sciences, Biology

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Lunit will participate in a Groundbreaking Prospective Study to Validate AI Performance

Retrieved on: 
Thursday, April 8, 2021
Medicine, Health sciences, Clinical medicine, Cancer screening, Breast imaging, Projectional radiography, Mammography, Screening, Breast cancer, Clinical trial

According to Lunit, this research is the first prospective study in Europe to validate the performance of AI in an actual clinical trial of screening mammography.

Key Points: 
  • According to Lunit, this research is the first prospective study in Europe to validate the performance of AI in an actual clinical trial of screening mammography.
  • Lunit INSIGHT MMG is an AI software developed by Lunit to detect breast cancer in mammography images.
  • "There have been multiple retrospective studies to validate AI performance, but there has not been any prospective studies to assess AI's clinical utility in an actual clinical setting," said Brandon Suh, CEO of Lunit.
  • In April, Dr. Strand will hold an online webinar featuring the findings on the previous studies with Lunit INSIGHT MMG and introduction of the newly initiated prospective study.

NanoString to Release First Quarter 2021 Operating Results and Host Conference Call on Monday, May 10, 2021

Retrieved on: 
Tuesday, April 6, 2021
Data management, Health, Technology, Genetics, Research, Science, Biotechnology, Cancer screening, NanoString Technologies, Conference call, Dial, Computer-assisted language learning

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release first quarter 2021 operating results after the close of the market on Monday, May 10, 2021.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release first quarter 2021 operating results after the close of the market on Monday, May 10, 2021.
  • Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
  • After registering, an email confirmation will be sent, including dial-in details and unique conference call codes for entry.
  • A replay of the call will be available beginning May 10, 2021 at 7:30pm ET through midnight on May 17, 2021.

Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer

Retrieved on: 
Thursday, April 1, 2021
Oncology, Health, Hospitals, Pharmaceutical, Cardiology, Biotechnology, Medicine, Clinical medicine, Medical specialties, Biopsy, Cancer screening, Interventional radiology, Liquid biopsy, Prostate cancer, Helmy Eltoukhy, Richard B. Lanman

Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patients status for residual disease, without the need for a tissue biopsy.

Key Points: 
  • Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patients status for residual disease, without the need for a tissue biopsy.
  • The Guardant Reveal blood test was introduced earlier this year and is Guardant Healths first commercially available liquid biopsy for clinical use in the management of early-stage cancer.
  • The incorporation of biologically relevant epigenomic signatures has been essential to increasing the sensitivity of the test to detect residual disease in early-stage cancers including CRC.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.

Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Health, Science, Research, Oncology, Medicine, Clinical medicine, Branches of biology, Cancer screening, DNA, Circulating free DNA, Medical signs, Biotechnology, Liquid biopsy, Biopsy, Biomarker, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH) sponsored a Science/AAAS Webinar, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment, which launched today.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH) sponsored a Science/AAAS Webinar, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment, which launched today.
  • During the panel discussion, Genetron Healths Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled Profiling cfDNA-based Biomarkers for the Early Detection of Cancer.
  • He also outlined the development and features of the Companys proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Companys liquid biopsy-based early screening test, HCCscreenTM; and explained potential R&D pathway for pan-cancer screening assay.
  • She also emphasized the advantages of liquid biopsy technology in cancer screening, and the benefits of blood tests in particular.

NYU Langone Seeks to Close the Gap in Colorectal Cancer Disparities with $2.2 Million Cohen Foundation Grant

Retrieved on: 
Wednesday, March 31, 2021
New York University, Infectious causes of cancer, Cancer screening, Langone, NCI-designated Cancer Center, NYU Langone Health, Colorectal cancer, Cancer, Manhattan, Health

Now, thanks to a $2.2 million grant from the Steven & Alexandra Cohen Foundation, NYU Langone Health is expanding its program to address this disparity in Brooklyn.

Key Points: 
  • Now, thanks to a $2.2 million grant from the Steven & Alexandra Cohen Foundation, NYU Langone Health is expanding its program to address this disparity in Brooklyn.
  • To detect colorectal cancer early, experts at NYU Langone recommend all adults with average risk, regardless of race, start screening at age 45-50.
  • Through seamless integration with NYU Langone's Perlmutter Cancer Center , a National Cancer Institute-designated Comprehensive Cancer Center, suspicious findings can be diagnosed and treated quickly and closer to home at Perlmutter Cancer CenterSunset Park .
  • "Colorectal cancer disparities are of critical concern, so we are eager to support NYU Langone's efforts to increase cancer screenings and expand care in these underserved communities," says Alex Cohen, president, Steven & Alexandra Cohen Foundation.

Bluestar Genomics Receives FDA Breakthrough Device Designation for First-of-Its-Kind Pancreatic Cancer Screening Test

Retrieved on: 
Wednesday, March 31, 2021
Oncology, Health, FDA, Medical devices, Diabetes, Genetics, Biotechnology, Medical specialties, Health, Clinical medicine, Oncology, Hereditary cancers, Gastrointestinal cancer, Pancreatic cancer, Cancer screening, Cancer, Prostate cancer, Causes of cancer, Breast cancer

Bluestar Genomics announces today it received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its proprietary noninvasive pancreatic cancer detection test in patients with new-onset diabetes.

Key Points: 
  • Bluestar Genomics announces today it received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its proprietary noninvasive pancreatic cancer detection test in patients with new-onset diabetes.
  • Bluestar Genomics pancreatic cancer test uses a standard blood draw to assess whether an individual has an abnormal epigenomic and genomic signature associated with pancreatic cancer.
  • Pancreatic cancer is the third-leading cause of cancer death in the U.S., surpassing common cancers such as breast and prostate.
  • With this designation, Bluestar Genomics test can help screen an estimated one million adults diagnosed annually with new-onset diabetes in the U.S. for early detection and treatment of pancreatic cancer to enable better patient outcomes.